Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10007616 | 0.85 | ALDH1A1 (1.00) | ALDH1A1HPGDLMNAATMKMT2A | |
| SCHEMBL14427584 | 0.80 | ALDH1A1 (0.76) | ALDH1A1HPGDLMNAATMKDM4E | |
| SCHEMBL3738440 | 0.79 | ALDH1A1 (0.72) | ALDH1A1HPGDLMNAKMT2AMEN1 | |
| SCHEMBL17967124 | 0.78 | ALDH1A1 (0.72) | ALDH1A1LMNAATMKMT2AMEN1 | |
| SCHEMBL26599232 | 0.78 | ATM (0.69) | ALDH1A1HPGDLMNAATMKMT2A | |
| SCHEMBL17967711 | 0.78 | ATM (0.69) | ALDH1A1HPGDLMNAATMKMT2A | |
| SCHEMBL3729367 | 0.78 | ATM (1.00) | ALDH1A1HPGDATMKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL21391938 | 0.77 | ATM (0.67) | ALDH1A1HPGDLMNAATMKMT2A | |
| SCHEMBL26599691 | 0.74 | ATM (0.63) | ALDH1A1HPGDLMNAATMKMT2A | |
| SCHEMBL834551 | 0.74 | TAAR1 (0.73) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428061-B2 | Autotaxin inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3253748-B1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| WO-2016124938-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | ENPP2, RNASE1, ATXN10 | ALDH1A1 4116/4885HPGD 3090/4885LMNA 443/4885 |
| US-10428061-B2 | Autotaxin inhibitors | ENPP2, ATXN10, RNASE1 | ALDH1A1 4227/4885HPGD 3259/4885LMNA 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.